StockMirror — Stock Screener

MEDANTA Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Medanta delivered a strong Q2 FY27 with 34% YoY revenue growth to INR 14,690 million, 60% YoY operating EBITDA growth to INR 3,701 million (25.2% margin vs 21% YoY), and 38% YoY PAT growth to INR 2,191 million. Noida achieved EBITDA breakeven within a year, validating the model's scalability. Volume growth was robust across clusters, driven by capacity additions and clinical talent hiring. The company has a robust expansion pipeline of ~3,450 beds over next few years with planned capex of over INR 6,000 crores. Key risks include regulatory uncertainty around oncology drug margin capping, seasonality in Q3, and construction delays at Pitampura. Overall outlook remains positive with management focused on long-term sustainable growth.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is focused on driving growth through volume, capacity expansion, and clinical talent additions, while simultaneously benefiting from operating leverage as hospitals scale up. The Noida EBITDA breakeven demonstrates the model's ability to achieve margins as scale increases. Management expl

About Global Health Limited (Medanta)

Global Health Limited (Medanta) (MEDANTA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More